Related Experiment Video
Updated: Apr 19, 2026
09:36
Isolated Pancreatic Islet Treatment and Apoptosis Measurement
Published on: May 2, 2025
1.1K
Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives
Manfredi Rizzo1, Noor Al-Busaidi, Ali A Rizvi
1University of South Carolina School of Medicine, Division of Endocrinology, Diabetes and Metabolism , Columbia, SC , USA.
Expert Opinion on Pharmacotherapy
|December 18, 2014
Summary
Dapagliflozin, a sodium glucose transporter 2 (SGLT-2) inhibitor, effectively lowers blood sugar in type-2 diabetes. It offers benefits beyond glucose control, including weight and blood pressure reduction, with a favorable safety profile.
Area of Science:
- Endocrinology and Metabolism
- Pharmacology
Background:
- Dapagliflozin represents a novel class of antidiabetic medications: sodium glucose transporter 2 (SGLT-2) inhibitors.
- Unlike traditional agents, SGLT-2 inhibitors lower blood glucose by reducing renal glucose reabsorption, independent of insulin secretion or sensitivity.
Discussion:
- The unique mechanism of SGLT-2 inhibitors allows for effective combination therapy with other antidiabetic agents, including insulin and incretin-based treatments.
- Dapagliflozin can be administered as monotherapy or in combination regimens (dual or triple therapy).
Key Insights:
- Dapagliflozin demonstrates efficacy in type-2 diabetes management, achieving modest yet significant reductions in HbA1c.
- Beyond glycemic control, dapagliflozin offers sustained, beneficial non-glycemic effects, including weight loss, improved plasma lipid profiles, and reduced systolic blood pressure.
- The agent exhibits a generally favorable safety profile and good tolerability.
Outlook:
- Further clinical studies are investigating the long-term cardiovascular safety and efficacy of SGLT-2 inhibitors in patients with type-2 diabetes.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:24Glucagon-like Receptor Agonists
1.4K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
1.0K
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
1.0K
01:06Oral Hypoglycemic Agents: Glinides
1000
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1000
01:24Type II Diabetes II: Pathophysiology
2
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
2